Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study.

ABSTRACT:

Background

The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the benefits and tolerability of TACE combined with second-line regorafenib in patients with unresectable advanced HCC and failure to first-line treatment.

Methods

This was a multicenter retrospective study of patients with progression after first-line sorafenib and/or lenvatinib between 01/2019 and 04/2020 at four tertiary hospitals in China. The patients were treated with TACE. Then, 5-7 days after the first TACE, the patients started taking regorafenib for 3 weeks every 4-week cycle. The overall survival (OS), time to progression (TTP), progre

SUBMITTER: Han Y 

PROVIDER: S-EPMC8529854 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature